SCHEMBL8289583

SCHEMBL8289583

CCOC(=O)c1c(NC(=O)c2cc3ccccc3o2)sc2c1CCC2

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 7/20 0.74
▸ HSD17B10 Q99714 7/20 0.74
▸ KDM4E B2RXH2 6/20 0.74
▸ MAPT P10636 4/20 0.74
▸ TP53 P04637 3/20 0.74
▸ MEN1 O00255 2/20 0.74
▸ KMT2A Q03164 2/20 0.74
▸ NPC1 O15118 1/20 0.74
▸ ESR1 P03372 1/20 0.74
▸ POLB P06746 1/20 0.74
▸ CASP3 P42574 1/20 0.74
▸ RAB9A P51151 1/20 0.74
▸ SMN1; SMN2 Q16637 1/20 0.74
▸ ESR2 Q92731 1/20 0.74
▸ SENP8 Q96LD8 1/20 0.74
▸ SENP7 Q9BQF6 1/20 0.74
▸ SENP6 Q9GZR1 1/20 0.74
▸ CNR2 P34972 2/20 0.66
▸ ALDH1A1 P00352 5/20 0.66
▸ NPSR1 Q6W5P4 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403591 0.85 NPC1 (1.00) HPGDHSD17B10KDM4EMAPTTP53
SCHEMBL15273119 0.83 ALDH1A1 (0.69) HPGDHSD17B10KDM4EMAPTTP53
SCHEMBL8289620 0.81 RAB9A (0.67) HPGDHSD17B10KDM4EMAPTTP53
SCHEMBL8290510 0.81 MAPT (0.77) HPGDHSD17B10KDM4EMAPTTP53
SCHEMBL5449432 0.79 ALDH1A1 (1.00) HPGDHSD17B10KDM4EMAPTTP53
SCHEMBL14328953 0.79 MAPT (0.74) HPGDHSD17B10KDM4EMAPTTP53
SCHEMBL3916162 0.79 MAPT (0.80) HPGDHSD17B10KDM4EMAPTTP53
SCHEMBL13561104 0.78 MAPT (1.00) HPGDHSD17B10KDM4EMAPTTP53
SCHEMBL8290769 0.77 MAPT (0.79) HPGDHSD17B10KDM4EMAPTTP53
SCHEMBL7892222 0.77 MAPT (0.84) HPGDHSD17B10KDM4EMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150051220-A1 COMPOUNDS FOR USE IN THERAPY GLUCOX BIOTECH AB (SE) 2015-02-19 — — US disclosed
EP-2825165-A1 THIOPHENE-BASED COMPOUNDS EXHIBITING NOX4 INHIBITORY ACTIVITY AND USE THEREOF IN THERAPY Glucox Biotech AB (SE) 2015-01-21 — — EP disclosed
WO-2013135803-A1 THIOPHENE-BASED COMPOUNDS EXHIBITING NOX4 INHIBITORY ACTIVITY AND USE THEREOF IN THERAPY GLUCOX BIOTECH AB (SE) 2013-09-19 — — WO disclosed
WO-2005033102-A2 THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMPHORA DISCOVERY CORPORATION (US) 2005-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051220-A1 COMPOUNDS FOR USE IN THERAPY XDH, PNPO, OAT HPGD 33/4885HSD17B10 301/4885KDM4E 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback